Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Inclusion Criteria:

• Patients diagnosed with epithelial ovarian cancer, fallopian tube cancer, or peritoneal cancer based on histologic findings obtained from biopsy/surgery and having a histologic type of high-grade serous cancer.
• In the absence of a mutation of the BRCA gene (no germline mutation should be identified, not in the case of a somatic mutation)
• Recurrence within 6 months after platinum-based chemotherapy.
• ECOG performance 2 points or less.
• Blood tests performed within 2 weeks of enrollment meet the following results: Neutrophil > 1,500/mm3; Platelet > 100,000/mm3; Hemoglobin > 9.0 g/dL; Total bilirubin < 1.5 x upper limit of normal (ULN); AST/ALT < 3.0 x ULN (or < 5 x ULM in case of liver metastases); Creatinine < 1.5 x ULN; Electrolytes should be within normal limits.
• Patients who understand the content of the study description and voluntarily agree in writing.
• Patients who are willing and able to adhere to the visit schedule, treatment plan, laboratory tests, and other testing procedures.

Exclusion Criteria:

• Patients previously treated with three or more anticancer regimens. Maintenance therapy is not considered a separate regimen (eg> paclitaxel-carboplatin-bevacizumab therapy). In the combined chemotherapy, when one drug is subtracted due to toxicity, the regimen is not counted as a change (Eg> paclitaxel-carboplatin chemotherapy, paclitaxel was discontinued due to neurotoxicity and carboplatin alone was not considered as a change of regimen).
• Previous refractory to ovarian cancer chemotherapy.
• Patients diagnosed with other tumors other than ovarian cancer for the last 5 years (not CIS).
• pregnant woman.
• Patients with uncontrolled infection.
• In the case of congenital immune disease or acquired immune deficiency syndrome.
• Women in lactation.
• History with Grade 3 or higher peripheral neuropathy.
• History of hypersensitivity reactions to PLD or bortezomib.
• If the physician is judged to have any serious illness or medical condition for which the patient is not suitable for the study.
• Patients with confirmed BRCA somatic mutations.
• Patients with acute diffuse infiltrative lung disease and cardiovascular disease.